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INTRODUCTION
IgA nephropathy is the most common chronic
glomerulopathy in children and young adults [1].
Although most of the early studies on pediatric IgA
nephropathy concluded that it was a benign condition
[2,3], recent data have shown that a significant
proportion of children progress to end-stage renal
disease [4–6]. A recent study from Memphis,
Tennessee, USA, showed that the predicted 10- and 20-
year renal survival rates in Caucasian children with IgA
nephropathy were 91% and 80%, respectively [7].
Therefore, it is now obvious that IgA nephropathy in
children is not as benign as previously thought.
Physicians caring for children with IgA nephropathy
need to be aware of this risk of progression to renal
insufficiency and make treatment a priority. Moreover,
strict attention needs to be given to modify any
coexisting morbidities that may further predispose
young patients to develop renal deterioration, such as
obesity, hypertension and dyslipidemia.
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PAUCITY OF EVIDENCE-BASED GUIDELINES IN
CHILDREN
As the number of patients with IgA nephropathy in
each individual pediatric center is relatively small, there
are very few randomized control trials in pediatric pa-
tients compared to adults. This is further compounded
by the marked differences in the natural history of the
disease in children compared to adults. Most pediatric
patients with progressive IgA nephropathy have an
insidious deterioration in renal function and do not
reach end-stage renal disease until adulthood.
Therefore, the common outcome measure of pro-
gressive renal failure is less applicable in pediatric
studies, since few if any children are likely to reach
this end point during their pediatric years. Most of the
surrogate markers of outcomes that have been used in
pediatric studies, such as doubling of serum creatinine
and reduction of proteinuria, have not been validated
as being meaningful outcome measures, and so the
conclusions elucidated from these studies may be
Department of Pediatrics, University of California, Davis, USA.
Address correspondence and reprint requests to: Dr. Keith K. Lau, Department of Pediatrics, University of California, Davis, 2516 Stockton
Boulevard, Sacramento, CA 95817, USA.
Fax: (+1) 916–7340629; E-mail: keith.lau@ucdmc.ucdavis.edu
Hong Kong J Nephrol • October 2007 • Vol 9 • No 2 71
Treatment of pediatric IgA nephropathy
inappropriate. Notwithstanding these caveats, the small
number of pediatric studies that have been performed
have contributed to a better understanding of this
disease and do provide data that can be useful to the
health care provider in managing this common disease.
PHARMACOLOGIC AGENTS IN TREATMENT OF
PEDIATRIC IGA NEPHROPATHY
The following pharmacologic agents and therapeutic
options have been studied in either adults or children.
Corticosteroids
Corticosteroids have been widely used in pediatric
patients with moderate to severe IgA nephropathy
(characterized by heavy persistent proteinuria, renal
insufficiency or hypertension). However, it is quite
difficult to draw any conclusion on their effectiveness
in the preservation of renal function as there are wide
discrepancies in the studies with respect to length of
follow-up, doses and routes of steroids used and the
use of concomitant medications. Also, some of these
studies were uncontrolled, making it difficult to
ascertain if the improvements in laboratory or clinical
data were related to the intervention or to a part of the
natural history of the disease itself [8–20]. There have
been two randomized trials on the use of steroids in
children to date [10,12]. In the first study, 20 children
were enrolled in a crossover trial. Each patient was
initially treated with oral prednisone and then switched
to placebo after 12 weeks. The efficacy was assessed
by using surrogate end points including improvements
in microscopic hematuria and proteinuria. Treatment
with prednisone failed to show any advantage in that
study [10]. However, as most of the children in that
study had either normal or mild histologic changes, and
the mean protein excretion was around 500 mg/day,
they would be at low risk of disease progression and
not be likely to merit any therapy in the first place. The
other recent randomized study from Japan involved
treatment regimens that included prednisone plus
azathioprine versus warfarin and dipyridamole [12].
Although the study group demonstrated a significant
reduction in proteinuria compared to the control group,
the regimens that were used in the study are not popular
outside Japan.
Although nephrotic syndrome is not a common
presenting feature of children with IgA nephropathy, a
subset of patients with IgA nephropathy present with
nephrotic syndrome and have minimal change histol-
ogy on their biopsies; these children do rapidly and
completely respond to steroids, similar to children with
idiopathic steroid-sensitive nephrotic syndrome. Clive
et al reviewed the literature and concluded that other
than higher serum IgA levels and a slower response to
steroids, patients with nephrotic syndrome and IgA
nephropathy with minimal change on biopsy are
indistinguishable from other patients with minimal
change disease [21]. Since in a study that described
200 consecutive necropsies, 4% of non-IgA nephro-
pathy patients were found to have IgA deposits in
their mesangium [22], it is still not clear whether the
presence of IgA in the mesangium of patients with
minimal change histology represents a true subset of
IgA nephropathy or is an incidental finding. Although
there is no randomized controlled trial to support this
approach, steroids are recommended in pediatric IgA
nephropathy patients with nephrotic syndrome [23,24].
Hence, although corticosteroids have been
recommended in patients with moderate to severe IgA
nephropathy, the recommendations are based on
anecdotal studies before the widespread use and
availability of angiotensin converting enzyme (ACE)
inhibitors. Most pediatric nephrologists would now
consider administering steroids only after the failure
of ACE inhibitors and/or angiotensin receptor blockers
(ARBs), except perhaps in rapidly progressive
glomerulonephritis or with severe nephrotic–nephritic
syndrome.
Angiotensin blockade
ACE inhibitors have been used in IgA nephropathy to
reduce proteinuria by reducing intraglomerular pressure
and by improving the permeability characteristics of the
glomerular basement membrane [25]. Small-scale
prospective studies in adults have also advocated the
addition of ARBs for additional benefit [26–29]. The
recently published COOPERATE study, in which almost
50% of the patients had IgA nephropathy, showed that
compared to monotherapy, a combination of ACE
inhibitors and ARBs was more effective in reducing
proteinuria and slowing the progression of renal failure
[30]. The ongoing ACEARB study is the first multicenter
open-label randomized clinical trial to test whether
angiotensin blockade would decrease the risk of renal
deterioration in patients with IgA nephropathy. Patients
3–60 years old with mild clinical features at onset,
including those with normal renal function, normal blood
pressure and proteinuria of < 1 g/day are being enrolled.
Patients are to be randomized to receive ramipril,
irbesartan or supportive therapy and will be followed
for 5 years or when the end point of the study (50%
increase in proteinuria) is reached [31]. Unless clinical-
ly contraindicated, such as in the setting of rapid
deterioration of renal function, we are now treating all
our patients who have heavy persistent proteinuria with
ACE inhibitor and/or ARB irrespective of their blood
pressure. Usually, we start patients on a lower dose and
then titrate up according to their response. Recent studies
also suggest that aldosterone blockade may have a further
additive effect in reducing proteinuria and retarding
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progression of renal disease [32]. However, until further
studies become available, the routine use of aldosterone
blockade cannot be recommended in patients with IgA
nephropathy, especially considering the risk of
hyperkalemia with this combination.
Immunosuppressive medications
A more aggressive approach to the treatment of severe
pediatric IgA nephropathy with immunosuppressive
medications has been reported by some, although most
of the studies related to this were not performed in a
large-scale, prospective and randomized fashion.
Azathioprine
Azathioprine combined with oral steroids was evaluated
in 10 children with IgA nephropathy [9]. These children
had proteinuria of > 1 g/day, elevated blood pressure
and renal insufficiency. Treatment consisted of daily
oral prednisone (60 mg/m2/day, maximum 60 mg) with
azathioprine (2–3 mg/kg/day) for 8 weeks, followed
by alternate day oral prednisone at 60 mg/m2 for another
10 months. The treated patients showed an improvement
in protein excretion. Since these children were not
treated with ACE inhibitors, the results suggest that oral
steroids and azathioprine may be useful in reducing
proteinuria and in a group of children with relatively
severe presentation [9]. A randomized trial study from
the Japanese Pediatric IgA Nephropathy Treatment
Study Group compared the efficacy of a regimen
comprised of oral prednisone and azathioprine versus
heparin–warfarin and dipyridamole [12]. After 2 years
of treatment, there was no difference in mean creatinine
clearance between the two groups. However, in the
steroid/azathioprine group, there was a significant
improvement in proteinuria and no increase in the
percentage of glomeruli showing sclerosis upon re-
biopsies. Although this study is the largest randomized
controlled trial in the treatment of pediatric IgA
nephropathy, the treatment regimen that included
heparin, warfarin and dipyridamole is not widely used
outside Japan. Also, apparently very few of the subjects
were treated with ACE inhibitors and the observation
of significant reduction in proteinuria in the treatment
group might also be achieved with ACE inhibitors. The
long-term benefit of prevention of progression to renal
failure with this regimen is still unclear.
Mycophenolate mofetil
To date, there are only four prospective randomized
controlled trials in adult patients with IgA nephropathy
to study the clinical efficacy of mycophenolate mofetil
(MMF) [33–36], and the results have been conflicting.
The studies from USA and Belgium showed no benefit
[17,33], while the studies from Hong Kong and China
suggested that MMF treatment had beneficial effects
in lowering proteinuria [34,36]. Although the results
of using MMF in adults may be encouraging, there are
currently no data in children evaluating the efficacy of
MMF in IgA nephropathy. The North American IgA
Nephropathy Study intended to study the effectiveness
of MMF versus placebo in children and adults after 3
months of pretreatment with ACE inhibitors and fish
oil. However, the children enrolled in the study all
became better after 3 months of ACE inhibitor and fish
oil, and no longer qualified for the study [37]. An
evidence-based recommendation for the use of MMF
in pediatric patients, therefore, cannot be made at the
present moment.
Cyclophosphamide
Although early reports [38–40] showed conflicting
results on the capability of cyclophosphamide to slow
the progression of renal function deterioration, a recent
randomized trial from the United Kingdom has suggested
that cyclophosphamide may be beneficial in patients with
IgA nephropathy and renal insufficiency [41]. The study
consisted of 38 IgA nephropathy patients with
hypertension and renal insufficiency (serum creatinine
> 1.5 mg/dL). None of the patients was given an ARB
for blood pressure control. The treatment group received
oral prednisone and cyclophosphamide followed by
azathioprine while the control group did not receive
any immunosuppressant. The treatment group had
significantly better renal outcome compared to the
controls. Renal survival rates at 5 years were 72% and
6% in the treatment and control groups, respectively.
Similar data in children are lacking, making it difficult
to justify the use of such a potentially toxic agent in
pediatric patients except in high-risk situations.
Cyclosporin
In a randomized prospective single blind study from
Hong Kong, 19 Chinese adults with proteinuria of > 1.
5 g/day were randomized to receive either cyclosporin
(5 mg/kg/day) or placebo [42]. Although the treatment
group had a significant reduction in proteinuria, the
authors observed an increase in serum creatinine and
reduction in glomerular filtration rate in the treatment
group even though the plasma cyclosporin levels were
maintained in a very tight range. The therapeutic role
of cyclosporin in the treatment of IgA nephropathy is
still unknown.
Leflunomide
A recent randomized study in adults with IgA
nephropathy compared the efficacy of leflunomide with
fosinopril [43]. The leflunomide treated group showed
a significant decrease in proteinuria, but this was
comparable to the group treated solely with fosinopril.
Based on the current data, we are not able to recom-
mend the usage of leflunomide in children with IgA
nephropathy [43].
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Fish oil
Donadio et al, in an elegant randomized controlled trial,
demonstrated that treatment with fish oil in adults with
IgA nephropathy delayed the rate of renal function
deterioration [44]. The study did include a few pediatric
patients. However, a recent meta-analysis of all
published studies up to 1997 concluded that fish oil
is of minimal benefit [45]. Moreover, in a recent
randomized trial of alternate day prednisone or daily
omega-3 fatty acids in children and young adults with
IgA nephropathy, children treated with fish oil failed
to show benefit over placebo in slowing disease
progression [46]. Although the data on the beneficial
effect of fish oil on retarding disease progression in
IgA nephropathy are conflicting, some authors do use
it, since it is very safe, with minimal side effects. Until
more data is available however, especially in children,
fish oil is not recommended as a routine treatment in
pediatric patients with IgA nephropathy.
Vitamin E
In a randomized, double-blinded study in children with
very mild but biopsy-proven IgA nephropathy, patients
treated with vitamin E had significant reduction of
proteinuria [47]. Children in the study who were treated
with vitamin E had a reduction in their urine protein to
creatinine ratio (mg/mg) from 0.31 to 0.24 at 1 year,
while the urine protein to creatinine ratio in the control
group increased from 0.52 to 0.64. Although the authors
suggest that vitamin E could be useful in reducing
proteinuria, long-term follow-up is needed to determine
its efficacy in the preservation of renal function,
especially in patients who are more likely to benefit
from any intervention, i.e. those with more severe
disease.
Anti-clotting agents
Warfarin and dipyridamole have been used for a long
time in Japan for the treatment of IgA nephropathy.
Yoshikawa and Ito demonstrated that after 2 years of
combined therapy with prednisolone, azathioprine,
heparin, warfarin and dipyridamole, patients showed
better outcome compared to those randomized to
heparin–warfarin and dipyridamole therapy [48]. Also,
the treatment group had reduced immunologic renal
injury and less sclerosed glomeruli, which suggested
a benefit in slowing the progression of renal
deterioration. Urokinase has also been used in the
treatment of IgA nephropathy in non-randomized trials
[49–51]. A recent study from China showed beneficial
effects of monthly intravenous urokinase for 10 days
[52]. Combined with benazepril, the authors dem-
onstrated that the regimen was more effective in re-
ducing proteinuria and slowing renal deterioration
than benazepril alone. Hence, warfarin, dipyridamole
and urokinase have all been used either alone or in
combination with other agents in the treatment of IgA
nephropathy with beneficial effects; however, there
are still insufficient data to recommend the routine
usage of such agents in clinical practice.
Tonsillectomy
Most of the data promoting tonsillectomy are from
adult studies. A recent study of 70 adult patients by
Sato et al, who used doubling of serum creatinine as a
surrogate marker of poor renal outcome, provided
evidence on the efficacy of tonsillectomy [53]. The
study included adult patients with moderate IgA
nephropathy with serum creatinine > 1.5 mg/dL.
Patients were divided into three treatment groups:
steroids plus tonsillectomy, steroids alone, and
supportive therapy only. Doubling of serum creatinine
occurred in 16% of patients in the steroid plus
tonsillectomy group compared to 64% in the steroid
group and 73% in the supportive group. In another
retrospective study in Japan with 118 patients who were
followed for over 20 years [54], renal survival in
patients with or without prior tonsillectomy was 90%
and 64%, respectively. Also, in a recent prospective
randomized study by Kawasaki et al, the efficacy of
tonsillectomy was studied in 32 Japanese children [55].
Sixteen children who received tonsillectomy and pulse
steroids were compared to another 16 children who
were treated with oral steroids, warfarin, dipyridamole
and mizoribine (PWDM). There were no untreated
controls in the study. The authors concluded that
tonsillectomy plus pulse steroids are as effective as the
PWDM regimen in controlling proteinuria, and able to
prevent flares of IgA nephropathy from tonsillitis.
It is obvious that a study that involves a surgical
procedure such as tonsillectomy cannot be blinded, and
the treatment protocols employed in these studies are
not widely used in other parts of the world. At present,
there are insufficient data to recommend tonsillectomy
as a safe and viable treatment option for children with
IgA nephropathy.
RECOMMENDED APPROACH
Since there is no specific treatment for patients with
IgA nephropathy, the primary goal of management is
to preserve renal function and slow down renal
deterioration.
The Figure depicts an algorithm that we are
currently using in our center for children with IgA
nephropathy. However, we state that the current
treatment of IgA nephropathy in pediatric patients is
not guided by results of well-designed pediatric
randomized controlled trials that employed appro-
priate outcome measures, but on data extrapolated
from adult studies.
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Although we do not recommend any specific
treatment for pediatric patients with clinically mild IgA
nephropathy, we do recommend controlling all other
potential risk factors for disease progression such as
hypertension. In one of our previous institutions, 30%
of children with biopsy-proven IgA nephropathy had
elevated blood pressure at presentation [56]. The first-
line medications that we use to treat hypertension in
this setting are ACE inhibitors and/or ARBs. Patients
with mild IgA nephropathy who have normal blood
pressure, normal renal function, and only low-grade
proteinuria (urine protein to creatinine ratio < 1.0)
need no treatment. Similarly, recurrent macroscopic
hematuria is self-limiting and requires no specific
treatment.
Patients with persistent proteinuria (urine protein
to creatinine ratio > 1, or lower if there is parental an-
xiety), even without hypertension, are also managed
by angiotensin blockade with the addition of fish oil.
Patients with rapidly progressive deterioration of
renal function, or patients in whom biopsy shows more
than 20% crescents, are usually treated with three doses
of intravenous methylprednisone followed by oral
prednisone; fish oil and angiotensin blockade therapies
may also be added once renal function stabilizes. If
there is minimal or no response in 4–6 weeks, we would
consider adding a second immunosuppressive agent.
In the past, we have used either oral cyclophosphamide
or azathioprine. More recently, we are using MMF
instead at a dose of 600–1,200 mg/m2/day in two
divided doses. Patients presenting with nephrotic
syndrome are treated with oral prednisone at 2 mg/kg/
day with a maximum of 60 mg or 80 mg per day in
pre- and post-pubertal children, respectively. This is
then tapered once remission is achieved. If, after 4–6
weeks, no response is seen, additional immunosuppres-
sants are added.
Clinically, the most challenging scenario is when a
child has mild renal insufficiency and a moderate de-
gree of proteinuria with or without hypertension. Al-
though clinically mild, the patient is at risk of renal
deterioration. We usually closely follow the patient in
order to observe the patient for rapid renal function
deterioration. If clinically stable with no sign of rapid
renal progression, we usually start the patient on ACE
inhibitor. If the patient has signs of renal progres-
sion, we recommend alternate day oral prednisone at
1 mg/kg for 6 months. If there is no improvement or
rapid deterioration continues, we usually add an
immunosuppressant.
Figure. Approach to the treatment of pediatric patients with IgA nephropathy. ACE = angiotensin converting enzyme; ARB = angiotensin
receptor blocker; IV = intravenous.
Mild disease: normal renal 
function, no proteinuria
Urine protein to 
creatinine ratio > 1.0
Nephrotic syndrome or 
nephrotic range of proteinuria
Consider adding 
immunosuppressant
Administer 3 doses of IV 
methylprednisone 
followed by oral steroids
Biopsy with > 20% crescent 
or rapidly progressive renal 
insufficiency
ACE inhibitor ± 
ARB ± fish oil
Normal blood pressure
No treatment
Elevated blood pressure
No response
Oral prednisone 
plus ACE inhibitor 
± ARB
Remission;
taper steroid
No response
No response
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